Breaking News

Vineti Receives $13.8M Investment in Drug Development Software Platform

Aims to fast-track development and manufacture of cell and gene therapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Vineti, a cell and gene therapy software and analytics company, received $13.8 million in capital from GE Ventures, Mayo Clinic Ventures and DFJ and LifeForce Capital. The investment will be used to grow its team and support the delivery of its cloud-based software designed to improve patient access, accelerate treatment delivery, and promote safety and regulatory compliance for individualized cell therapies.   Within the oncology market, approximately $5.7 billion was invested in cell and gen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters